Biogen Inc (BIIB)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 4,293,100 | 5,114,100 | 5,316,400 | 11,639,400 | 12,422,500 |
Revenue | US$ in thousands | 9,835,600 | 10,173,400 | 10,981,700 | 13,444,600 | 14,377,900 |
Gross profit margin | 43.65% | 50.27% | 48.41% | 86.57% | 86.40% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $4,293,100K ÷ $9,835,600K
= 43.65%
Biogen Inc's gross profit margin has shown a declining trend over the past five years, starting at 86.40% in 2019 and decreasing to 74.24% in 2023. This indicates a decrease in the percentage of revenues remaining after accounting for the cost of goods sold. The decline in gross profit margin could be attributed to various factors such as increased production costs, pricing pressures, or changes in the product mix. It is important for Biogen Inc to closely monitor and address the factors affecting its gross profit margin to maintain profitability and strengthen its financial performance.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Biogen Inc
BIIB
43.65%
Amgen Inc
AMGN
29.22%
Bio-Techne Corp
TECH
66.39%
Gilead Sciences Inc
GILD
40.25%
Halozyme Therapeutics Inc
HALO
48.04%
Krystal Biotech Inc
KRYS
-76.46%
Moderna Inc
MRNA
-11.69%
Neurocrine Biosciences Inc
NBIX
50.57%
Regenxbio Inc
RGNX
-71.48%
Repligen Corporation
RGEN
-2.56%
Vericel Corp Ord
VCEL
68.64%